puromycin aminonucleoside and Cirrhosis

puromycin aminonucleoside has been researched along with Cirrhosis in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (37.50)18.2507
2000's3 (37.50)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Bollinger, C; Fitch, RM; Hayes, K; Warner, E; Wright, D1
Abraham, VC; Doyle, K; Gopalakrishnan, M; Gopalakrishnan, S; Lee, CH; Leys, L; Ma, J; McGaraughty, SP; Nikkel, AL; Olson, L; Pratt, S; Putman, B; Salte, K; Su, Z; Widomski, D; Zhu, CZ1
Ding, W; Li, J; Wang, H; Yu, L; Zhao, Y1
Doi, N; Hotta, O; Miyazawa, S; Natori, Y; Nishikawa, K1
Bertho-Ruault, C; de Gouville, AC; Gellibert, F; Grygielko, ET; Huet, S; Laping, NJ; Mathews, N; Nguyen, VL; Patikis, A; Woolven, J1
Bustos, C; Egido, J; González-Cuadrado, S; Guijarro, C; Ortiz, A; Plaza, JJ; Ruiz-Ortega, M1
Drukker, A; Eddy, AA1
Buch, S; Eddy, AA; Jones, CL; Liu, E; McCulloch, L; Post, M1

Other Studies

8 other study(ies) available for puromycin aminonucleoside and Cirrhosis

ArticleYear
Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
    BMC nephrology, 2020, 06-15, Volume: 21, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Biomarkers; Disease Models, Animal; Female; Fibrosis; Glomerulosclerosis, Focal Segmental; Injections; Kidney; Membrane Glycoproteins; Podocytes; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley

2020
A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injury.
    European journal of pharmacology, 2016, Oct-05, Volume: 788

    Topics: Adenosine Kinase; Animals; Basement Membrane; Cytoprotection; Fibrosis; Kidney; Male; Mice; Podocytes; Protein Kinase Inhibitors; Puromycin Aminonucleoside; Rats

2016
Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis.
    Life sciences, 2004, Feb-13, Volume: 74, Issue:13

    Topics: Angelica sinensis; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibiotics, Antineoplastic; Astragalus Plant; China; Drugs, Chinese Herbal; Enalapril; Fibrosis; Humans; Kidney; Male; Medicine, Chinese Traditional; Nephrosis; Phytotherapy; Plant Preparations; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Regression Analysis; Transforming Growth Factor beta; Transforming Growth Factor beta1

2004
Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats.
    Kidney international, 2004, Volume: 65, Issue:6

    Topics: Animals; Fibrosis; Gene Expression; Heparin; Interleukin-4; Kidney; Male; Mast Cells; Puromycin Aminonucleoside; Rats; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta

2004
Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Journal of medicinal chemistry, 2006, Apr-06, Volume: 49, Issue:7

    Topics: Activin Receptors, Type I; Acute Disease; Administration, Oral; Animals; Benzamides; Collagen Type I; Collagen Type I, alpha 1 Chain; Dimethylnitrosamine; Fibrosis; Kidney; Liver Cirrhosis; Male; Models, Molecular; Protein Serine-Threonine Kinases; Puromycin Aminonucleoside; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; RNA, Messenger; Structure-Activity Relationship

2006
Expression of leucocyte chemoattractants by interstitial renal fibroblasts: up-regulation by drugs associated with interstitial fibrosis.
    Clinical and experimental immunology, 1996, Volume: 106, Issue:3

    Topics: Animals; Chemokine CCL2; Chemokine CXCL10; Chemokines; Chemokines, CXC; Connective Tissue; Connective Tissue Cells; Cyclosporine; Cytokines; Fibroblasts; Fibrosis; Kidney; Nephritis, Interstitial; Puromycin Aminonucleoside; Rats; RNA, Messenger; Up-Regulation

1996
Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
    Journal of the American Society of Nephrology : JASN, 1998, Volume: 9, Issue:2

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol; Collagen; Female; Fibronectins; Fibrosis; Kidney; Lipid Peroxides; Lipoproteins, LDL; Liver; Lovastatin; Macrophages; Microscopy, Fluorescence; Nephrotic Syndrome; Organ Size; Probucol; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Time Factors; Transforming Growth Factor beta; Treatment Failure; Vitamin E

1998
Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis.
    Kidney international, 1991, Volume: 40, Issue:6

    Topics: Albuminuria; Animals; Chronic Disease; Creatinine; Disease Models, Animal; Extracellular Matrix Proteins; Female; Fibrosis; Gene Expression; Glycoproteins; Macrophages; Metalloendopeptidases; Nephrosis; Puromycin Aminonucleoside; Rats; Rats, Inbred Lew; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta

1991